Zydus Lifesciences Limited’s subsidiary, Zydus Pharmaceuticals (USA) Inc., has received tentative approval from the United States Food and Drug Administration (USFDA) for Gabapentin Tablets, the company said via an exchange filing.
The recommended daily dose is 300 mg or 600 mg (Gralise Tablets).
Gabapentin tablets are indicated for the management of Postherpetic Neuralgia (PHN).
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya.
Kalyan Crime Branch Arrests Man For Allegedly Strangling Lover To Death Over Petty Dispute In Dombivli
Navi Mumbai News: Turbhe Police Conducts Night-Long Combing Operation, Arrests Illegal Activities In Major Crackdown
Girls Outshine Boys In Maharashtra As ICSE And ISC Results Achieve Near-Perfect Pass Rates
Indian Railways Launches 'Chhatrapati Shivaji Maharaj Circuit' Heritage Train Tour From June 9; Check Full Tour Itinerary
Gabapentin Tablets had annual sales of USD 90 mn in the United States (IQVIA MAT Dec. 2022).
The group now has 343 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.
